Fiorentina Ascenzioni

Sapienza, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Editorial: ESKAPEing host endogenous and exogenous defenses: new insights into the ability of multidrug- resistant bacteria to overcome host defenses and antimicrobial compounds activity.

Editorial: ESKAPEing host endogenous and exogenous defenses: new insights into the ability of multidrug- resistant bacteria to overcome host defenses and antimicrobial compounds activity.

Journal: Frontiers in cellular and infection microbiology

Published: March 23, 2026

Exploration of the aromatic abietane diterpenoid scaffold in the development of ArnT-mediated colistin resistance inhibitors.

Exploration of the aromatic abietane diterpenoid scaffold in the development of ArnT-mediated colistin resistance inhibitors.

Journal: RSC advances

Published: November 26, 2025

Long-term therapy with elexacaftor/tezacaftor/ivacaftor improves cystic fibrosis lung disease and monocyte function.

Long-term therapy with elexacaftor/tezacaftor/ivacaftor improves cystic fibrosis lung disease and monocyte function.

Journal: Respiratory medicine

Published: November 08, 2025

Corrigendum to "Development of nanovehicles for co-delivery of colistin and ArnT inhibitors" [Int. J. Pharm 675 (2025)125515].

Corrigendum to "Development of nanovehicles for co-delivery of colistin and ArnT inhibitors" [Int. J. Pharm 675 (2025)125515].

Journal: International journal of pharmaceutics

Published: April 29, 2025

Development of nanovehicles for co-delivery of colistin and ArnT inhibitors.

Development of nanovehicles for co-delivery of colistin and ArnT inhibitors.

Journal: International journal of pharmaceutics

Published: December 03, 2024

Cefiderocol activity against planktonic and biofilm forms of β-lactamase-producing pseudomonas aeruginosa from people with cystic fibrosis.

Cefiderocol activity against planktonic and biofilm forms of β-lactamase-producing pseudomonas aeruginosa from people with cystic fibrosis.

Journal: Journal of global antimicrobial resistance

Published: November 08, 2024

Staphylococcus aureus colonizing the skin microbiota of adults with severe atopic dermatitis exhibits genomic diversity and convergence in biofilm traits.

Staphylococcus aureus colonizing the skin microbiota of adults with severe atopic dermatitis exhibits genomic diversity and convergence in biofilm traits.

Journal: Biofilm

Published: August 04, 2024

Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy.

Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy.

Journal: Archives of gynecology and obstetrics

Published: October 12, 2022

Skin dysbiosis and Cutibacterium acnes biofilm in inflammatory acne lesions of adolescents.

Skin dysbiosis and Cutibacterium acnes biofilm in inflammatory acne lesions of adolescents.

Journal: Scientific reports

Published: July 25, 2022

Elexacaftor/tezacaftor/ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis.

Elexacaftor/tezacaftor/ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis.

Journal: The European respiratory journal

Published: April 05, 2022

The Pseudomonas aeruginosa DksA1 protein is involved in H2O2 tolerance and within-macrophages survival and can be replaced by DksA2.

The Pseudomonas aeruginosa DksA1 protein is involved in H2O2 tolerance and within-macrophages survival and can be replaced by DksA2.

Journal: Scientific reports

Published: March 14, 2022

Editorial: Microbial Biofilms in Chronic and Recurrent Infections.

Editorial: Microbial Biofilms in Chronic and Recurrent Infections.

Journal: Frontiers in microbiology

Published: October 27, 2021

Showing 1-12 of 36

Last Updated: 09/26/2026